We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

78 hedge funds and large institutions have $908M invested in Rhythm Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 21

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

2.51% less ownership

Funds ownership: 93.63% → 91.11% (-2.5%)

6% less capital invested

Capital invested by funds: $970M → $908M (-$61.6M)

8% less funds holding

Funds holding: 85 → 78 (-7)

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

Holders
78
Holders Change
-7
Holders Change %
-8.24%
% of All Funds
1.78%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.14%
New
10
Increased
38
Reduced
21
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$24M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$17.1M
3
State Street
State Street
Massachusetts
+$15.2M
4
RCM
RA Capital Management
Massachusetts
+$12.9M
5
BlackRock
BlackRock
New York
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$32.3M
2
TG
TRV GP
Massachusetts
-$31.6M
3
DM
Deerfield Management
New York
-$10.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.35M
5
PA
Perceptive Advisors
New York
-$4.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.09M +$1.84M +58,198 +122%
AA
27
ALPS Advisors
Colorado
$1.76M +$649K +20,524 +51%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.76M +$710K +22,481 +59%
Man Group
29
Man Group
United Kingdom
$1.64M +$1.78M +56,360 New
GX
30
Greylock XII
California
$1.6M +$1.73M +54,749 New
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$1.52M +$461K +14,586 +39%
TOPU
32
Trustees of Princeton University
New Jersey
$1.39M +$1.51M +47,643 New
SSA
33
Schonfeld Strategic Advisors
New York
$1.37M -$1.55M -48,900 -51%
Russell Investments Group
34
Russell Investments Group
United Kingdom
$1.1M -$671K -21,243 -36%
PPA
35
Parametric Portfolio Associates
Washington
$990K +$196K +6,218 +22%
Squarepoint
36
Squarepoint
New York
$956K +$435K +13,770 +73%
ClearBridge Investments
37
ClearBridge Investments
New York
$899K -$1.49K -47 -0.2%
Swiss National Bank
38
Swiss National Bank
Switzerland
$834K – – –
TA
39
Teachers Advisors
New York
$810K +$233K +7,360 +36%
Citigroup
40
Citigroup
New York
$801K +$811K +25,678 +1,462%
Morgan Stanley
41
Morgan Stanley
New York
$777K -$94.6K -2,994 -10%
Adage Capital Partners
42
Adage Capital Partners
Massachusetts
$729K +$790K +25,000 New
TCM
43
Tekla Capital Management
Massachusetts
$726K +$787K +24,890 New
TCIM
44
TIAA CREF Investment Management
New York
$699K -$27.3K -864 -3%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$676K +$139K +4,400 +23%
Millennium Management
46
Millennium Management
New York
$560K -$294K -9,308 -33%
PP
47
PDT Partners
New York
$502K -$701K -22,193 -56%
CS
48
Credit Suisse
Switzerland
$466K +$226K +7,154 +81%
TD Asset Management
49
TD Asset Management
Ontario, Canada
$425K +$91.7K +2,903 +25%
VEA
50
Virtus ETF Advisers
New York
$410K -$326K -10,330 -42%
1
2
3 4

RYTM Hedge Fund Activity: Q3 2018 in Review

78 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2018, worth a combined $908M — down 6.3% from $970M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RYTM and 10 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 38 added.

The largest buyer was Janus Henderson Group, adding an estimated $24M. The largest seller was OrbiMed, cutting an estimated $32.3M.

  • 78 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2018, down from 85 in Q2 2018.
  • Funds reported $908M of Rhythm Pharmaceuticals stock for Q3 2018, down 6.3% quarter-over-quarter.
  • 10 funds opened new Rhythm Pharmaceuticals positions in Q3 2018 and 17 closed out, a net change of -7 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q3 2018 was Janus Henderson Group, an estimated $24M added.
  • The largest Rhythm Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $32.3M sold.

Based on aggregated 13F filings for Q3 2018.